Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer

Chel Hun Choi1,5, Tae Heung Kang2, Joon Seon Song1,6, Young Seob Kim2, Eun Joo Chung3, Kris Ylaya1, Seokho Kim7, Sang Seok Koh8, Joon-Yong Chung13, Jae-Hoon Kim4 & Stephen M. Hewitt1

Pancreatic adenocarcinoma upregulated factor (PAUF) is a ligand of toll-like receptors (TLRs) and has been reported to be involved in pancreatic tumor development. However, the significance of PAUF expression in epithelial ovarian cancer remains unclear. We aimed to investigate the possible clinical significance of PAUF in epithelial ovarian cancer. We examined the link between PAUF and TLR4 in ovarian cancer cell lines. Recombinant PAUF induced cell activation and proliferation in ovarian cancer cell lines, whereas PAUF knockdown inhibited these properties. Subsequently, we assessed PAUF and TLR4 expression by immunohistochemistry on tissue microarray of 408 ovarian samples ranging from normal to metastatic. PAUF expression positively correlated with TLR4 expression. Overexpression of PAUF was associated with high-grade tumor \((p = 0.014)\) and chemoresistant tumor \((p = 0.017)\). Similarly, high expression of TLR4 correlated with advanced tumor stage \((p = 0.002)\) and chemoresistant tumor \((p = 0.001)\). Multivariate analysis indicated that PAUF\(^{\text{high}}\)/TLR4\(^{\text{high}}\), and PAUF\(^{\text{high}}\)/TLR4\(^{\text{high}}\) expression are independent prognostic factor for progression-free survival, while TLR4\(^{\text{high}}\) and PAUF\(^{\text{high}}\)/TLR4\(^{\text{high}}\) expression were independent prognostic factors for overall survival. Our results suggest that PAUF has a role in ovarian cancer progression and is a potential prognostic marker and novel chemotherapeutic target for ovarian cancer.

Ovarian cancer is the leading cause of gynecologic cancer-related deaths in the United States, accounting for 13,850 deaths annually\(^1\). Despite significant advances in diagnosis and treatment, more than 70% of affected women are diagnosed with advanced disease, and ovarian carcinoma remains the most lethal gynecologic tumor\(^2\)–\(^4\). This high mortality is attributed in part to the lack of reliable early detection method and inadequate primary treatment regimens resulting in rapid tumor recurrence, which is typically less responsive to current chemotherapy strategies, resulting in poor patient outcome\(^5\)–\(^8\). Thus, there is a great need for research studies into...

1Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. 2Department of Immunology, College of Medicine, Konkuk University, Chungju, 27478, Republic of Korea. 3Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, 20892, USA. 4Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, Republic of Korea. 5Departments of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea. 6Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea. 7Aging Research Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. 8Department of Biological Sciences, Dong-A University, Busan, 49315, Republic of Korea. Chel Hun Choi and Tae Heung Kang contributed equally to this work.

Correspondence and requests for materials should be addressed to J.-H.K. (email: jaehoonkim@yuhs.ac) or S.M.H. (email: genejock@helix.nih.gov)
the molecular pathogenesis of ovarian cancer to facilitate screening and to encourage the development of novel therapeutic strategies to prevent disease recurrence.

It is well appreciated that inflammation resulting from chronic infection and irritation is an important factor in cancer tumorigenesis and progression. In particular, numerous inflammatory cells and various cytokines are present in ascites fluid and ovarian cancer tissue. Furthermore, prior studies demonstrated that inflammatory mediators and cytokines produced by activated immune cells promote ovarian tumorigenesis and cancer progression. Although there is increasing evidence of the importance of inflammation in ovarian cancer progression, the source and target of the inflammatory signals are unknown. Among molecules involved in cancer-related inflammatory responses, toll-like receptors (TLRs) are pattern recognition receptors that have a crucial role in innate inflammation and innate immunity. As potential activators of NF-κB, TLRs are considered to be the gateway to inflammation and tumorigenesis. Furthermore, TLRs have also been detected in several malignant epithelial tumors and have been shown to promote cell proliferation, inhibit apoptosis, and lead to cell migration, invasion, and angiogenesis.

Pancreatic adenocarcinoma up-regulated factor (PAUF) is a novel tumor-specific protein that plays an important role in carcinogenesis and metastasis in several types of cancer. It has been associated with poor outcomes in cervical cancer. PAUF promotes both angiogenesis and vascular permeability in a mouse pancreatic cancer model. Furthermore, PAUF has been reported to be an endogenous ligand for TLR4 and can lead to activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), protein kinase B (AKT), and p-38 of the innate immunity TLR signaling pathway without activating NF-κB in a human leukemia cell line (THP-1). Thus, we hypothesized that the PAUF/TLR4 signaling pathway may play a role in the development of ovarian cancer and potentially be a novel target for treatment. The aim of this study was to examine the potential association between PAUF and TLR4 in ovarian cancer progression using ovarian cancer cell lines. Additionally, we assessed the clinical applicability of PAUF and TLR4 expression as a prognostic and predictive biomarker in ovarian cancers.

**Results**

**PAUF is linked to TLR4-mediated signaling and cell proliferation in ovarian cancer cell lines.** Given that PAUF activates TLR-mediated ERK signaling in pancreatic cancer, we examined its role in ovarian cancer. Since PAUF is an endogenous ligand for TLR4, we investigated whether PAUF could induce cancer cell activation and cancer proliferation via TLR4 using PAUF and TLR4 expressing ovarian cancer cell lines (A2780 and SKOV3). These two cell lines expressed TLR4 on the cell surface and intracellularly, as shown in Fig. 1A, and also expressed and secreted PAUF (Fig. 1B and C). For the knockdown of TLR4 in these cells, two kinds of TLR4 siRNAs (Sigma, MO) were transiently transfected into cells, and the TLR4 expression level was evaluated using FACS analysis and western blotting (Supplementary Fig. S1A). After 48 h post-transfection, TLR4 expression level was downregulated in all siRNA-transfected cells compared to control siRNA-transfected cells (Fig. 1D). To confirm ovarian cell activation by PAUF, starved A2780 and SKOV3 cells were treated with recombinant PAUF, and intracellular signaling cascades that are frequently important during tumor progression were detected using western blotting. Treatment of SKOV3 and A2780 cells with recombinant PAUF induced rapid activation of ERK, c-Jun N-terminal kinase (JNK), and p38 but not AKT (Fig. 1E). However, after transfection with TLR4 siRNA, activation of ERK, JNK, and p38 was reduced (Fig. 1F and Supplementary Fig. S2). The effect of silencing PAUF or TLR4 on cell proliferation was assessed in transfected A2780 and SKOV3 cells after evaluation of TLR4 and PAUF expression level by western blotting (Supplementary Fig. S1). Cell proliferation was significantly reduced in groups transfected with silencing siRNAs of PAUF or/and TLR4 compared to the group transfected with non-silencing control siRNA in both cell lines (Fig. 1G and Supplementary Fig. S3). The effect of recombinant PAUF treatment was investigated in transfected SKOV3 and A2780 cells with silencing siRNAs of PAUF or/and TLR4 to confirm the role of PAUF on ovarian cancer cell proliferation. Decreased proliferation in transfected SKOV3 and A2780 cells with PAUF siRNAs was completely recovered to the level of cells transfected with recombinant PAUF treatments. However, PAUF treatment didn’t change the decreased levels of proliferation in SKOV3 and A2780 cells transfected with a combination of both TLR4 and PAUF siRNAs. These findings demonstrate that PAUF is one of the critical factors which promote ovarian cancer cell proliferation, and TLR4 is associated with the proliferation mechanism mediated by PAUF. Collectively, our results indicate that PAUF acts on ovarian cancer cells in an autocrine and a paracrine manner to induce intracellular signaling cascades that are involved in tumor progression.

**High expression of PAUF and TLR4 is associated with advanced tumor phenotype.** We examined PAUF and TLR4 expression in human epithelial ovarian tissues by immunohistochemical staining. The tumor cells were positive for PAUF as a cytoplasmic pattern, whereas TLR4 showed membranous and cytoplasmic expression pattern. Representative immunohistochemistry images of PAUF and TLR4 are presented in Fig. 2. PAUF and TLR4 were more frequently expressed in carcinoma than benign or borderline tumor. Eighty-four of 182 cancers (46.2%) had high expression (cut-off value ≥ 197) of PAUF, and 91 of 182 cancers (50.0%) had high expression (cut-off value ≥ 135) of TLR4. Clinicopathological characteristics associated with PAUF and TLR4 expression are summarized in Table 1. PAUF and TLR4 expression gradually increased from benign to cancer (Fig. 3A and B and Table 1). PAUF immunoreactivity was significantly associated with high grade (p = 0.014), and TLR4 immunoreactivity was associated with advanced tumor stage (p = 0.002). In addition, PAUF and TLR4 expression levels were higher in serous tumors than in other histology (Table 1). In terms of chemosensitivity, PAUF and TLR4 expression correlated with chemoresistant tumor (p = 0.017 and p = 0.001, respectively) (Fig. 3C and D). These results indicate that high expression levels of PAUF and TLR4 are associated with more aggressive phenotypes in epithelial ovarian cancer.
The correlation between expression of PAUF and TLR4 was assessed in epithelial ovarian cancer and precancerous lesions. There was a weak, but statistically significant correlation between PAUF and TLR4 expression in cancer tissues ($r = 0.256$, $p = 0.001$), while there is no correlation in precancerous lesions (Fig. 4 and Supplementary Fig. S4). Furthermore, stronger correlation between PAUF and TLR4 expression was observed in advanced stages ($r = 0.279$, $p = 0.002$), grade 3 ($r = 0.346$, $p = 0.001$), chemosensitive ($r = 0.228$, $p = 0.010$) and serous ($r = 0.271$, $p = 0.003$) by subgroup analysis (Fig. 4 and Supplementary Fig. S4).

**High expression levels of PAUF and TLR4 predict shorter survival.** We next examined the relationships between expression of each protein and patient outcomes. Kaplan–Meier plots demonstrated that patients with high expression (cut-off value $\geq 197$) of PAUF displayed shorter progression-free survival (survival rate of
20.0 vs. 50.1%, \( p = 0.001 \) and overall survival (survival rate of 56.2 vs. 70.2%, \( p = 0.031 \)) than patients with low PAUF expression (cut-off value < 197). The high TLR4 expression (cut-off value \( \geq 135 \)) group had also shorter survival while the low TLR4 expression (cut-off value < 135) group had longer survival in progression-free survival (survival rate of 26.8 vs. 47.1%, \( p < 0.001 \)) and overall survival (survival rate of 48.3 vs. 80.4%, \( p = 0.003 \)) (Fig. 5).

When survival of patients with PAUF\textsuperscript{high}/TLR4\textsuperscript{high} expression was compared with survival of patients with PAUF\textsuperscript{low}/TLR4\textsuperscript{low} there is a significant difference in progression-free survival (survival rate of 7.7 vs. 54.7% months, \( p < 0.001 \)) and overall survival (survival rate of 44.5 vs. 87.8%, \( p < 0.001 \)) than patients who were PAUF\textsuperscript{low}/TLR4\textsuperscript{low} expression (Fig. 5).

Multivariate analysis data using Cox proportional hazard regression were summarized in Tables 2 and 3. FIGO stage was a significant risk factor for both progression-free survival and overall survival (\( p < 0.001 \) and \( p = 0.045 \), respectively). PAUF overexpression showed independent poor progression-free survival with a hazard ratio of 2.29 (\( p < 0.001 \)), while high TLR4 displayed poor progression-free survival and overall survival compared to low expression, as shown in Tables 2 and 3 (\( p = 0.019 \) and \( p = 0.038 \), respectively). Furthermore, the high of PAUF and TLR4 (PAUF\textsuperscript{high}/TLR4\textsuperscript{high}) expression was a significant risk factor for both progression-free survival [hazard ratio = 3.81 (95% CI, 1.98–7.30), \( p < 0.001 \)] and overall survival [hazard ratio = 4.40 (95% CI, 1.48–13.06), \( p < 0.008 \)].

Figure 2. Representative images of immunohistochemical staining of pancreatic adenocarcinoma upregulated factor (PAUF) and toll-like receptor 4 (TLR4) in human ovarian cancer specimens. The top row (A, B) represents normal ovarian tissue, middle row (C, D) shows immunoreactivity of ovarian carcinomas and the bottom row (E, F) indicates immunonegativity of ovarian carcinomas. The stromal cells of normal ovarian tissue show immunonegativity for PAUF and TLR4. The scale bar represents 100 \( \mu \)m.
In this study, we demonstrated that PAUF enhanced cancer cell growth through ERK, JNK, and p38 activation using two ovarian cancer cell lines (A2780 and SKOV3). Selective knockdown of TLR4 using siRNA significantly reduced the activation levels of ERK, JNK, and p38 and the growth rates of A2780 and SKOV3 cells. Subsequently, we investigated the prognostic significance of PAUF and TLR4 expression in epithelial ovarian tumors. PAUF and TLR4 protein expression was increased during carcinogenesis. Notably, overexpression of PAUF and TLR4 correlated with aggressive tumor phenotypes, including chemoresistance. Patients with PAUF and TLR4 overexpression had shorter median progression-free survival and overall survival. These findings suggest that PAUF participates in the progression of ovarian cancer via TLR4 signaling that activates ERK, JNK, and p38. Therefore, the assessment of PAUF and TLR4 expression can potentially serve as a new prognostic indicator predicting survival time, and can be helpful in management of patients with ovarian cancer.

The engagement of TLR4 signaling in cancer was revealed by previous studies. TLR4 signaling is upregulated in numerous ovarian epithelial cancers, and the level of expression correlates with increased cancer progression and chemoresistance to paclitaxel26–28. Recently, Luo et al. have suggested that TLR4 might stimulate serous ovarian carcinoma initiation, progression, and chemoresistance29. The poor outcome and chemoresistance of ovarian cancer patients with TLR4 overexpression in our study are consistent with those previous studies. However, previous data on the clinical significance of PAUF expression in ovarian cancer were limited. Kim et al. found positive staining for PAUF more frequently in mucinous adenocarcinoma than in mucinous cystadenoma and mucinous borderline tumor and showed that patients with PAUF-positive cancer tended to have shorter survival. They suggested that PAUF might be a prognostic marker for patients with an ovarian mucinous tumor30. Our data demonstrated that PAUF and TLR4 expression were increased from benign to advanced tumor (Fig. 3), and their correlation coefficient was increased in advanced stages (stage III/IV) and grade 3 compared to early stages (stage I/II) and grade 1/2 cancer specimens (Fig. 4). These data suggest that the PAUF and TLR4 is closely linked in the process of epithelial ovary cancer. The potential of PAUF/TLR4 as a prognostic marker was first investigated in the present study.

Ovarian cancer remains a very difficult disease to treat as most patients present at an advanced stage. Most patients respond to initial anticancer therapy but experience tumor recurrence within 3 years31. Chemoresistance is one of the major clinical problems compromising the successful treatment of ovarian cancer. Several mechanisms have been proposed to be involved in drug resistance, including decreased drug accumulation, alteration of drug transport, increased drug tolerance, and increased DNA repair activity32–34. Here, we propose that the PAUF/TLR4 signaling pathway is one of the mechanisms involved in drug resistance and is associated with poor prognosis of patients.

| Diagnosis     | No | PAUF Mean [95% CI] | p value | TLR4 Mean [95% CI] | p value |
|---------------|----|-------------------|---------|--------------------|---------|
| Normal        | 72 | 128 [118–138]     | <0.001  | 88 [76–100]        | <0.001  |
| Benign        | 69 | 106 [84–128]      | 0.506   | 76 [58–95]         | 0.075   |
| Borderline    | 62 | 152 [129–176]     | 0.018   | 123 [101–145]      | 0.001   |
| Cancer        | 205| 175 [165–185]     | 0.001   | 142 [132–153]      | 0.002   |
| Age           |    |                   |         |                    |         |
| <50           | 205| 156 [144–169]     | 0.302   | 129 [117–140]      | 0.052   |
| >50           | 164| 165 [154–177]     | 0.003   | 146 [133–158]      |         |
| Cell type     |    |                   |         |                    |         |
| Serous        | 164| 168 [158–178]     | 0.003   | 151 [140–161]      | <0.001  |
| Others        | 149| 141 [126–156]     | 0.003   | 101 [89–113]       |         |
| Stage         |    |                   |         |                    |         |
| I/II          | 60 | 173 [151–194]     | 0.309   | 116 [98–134]       | <0.001  |
| III/IV        | 140| 179 [167–191]     | 0.003   | 150 [137–164]      |         |
| Metastatic    | 52 | 160 [135–185]     | 0.014   | 176 [152–201]      |         |
| Grade         |    |                   |         |                    |         |
| 1/2           | 93 | 167 [153–180]     | 0.014   | 142 [127–157]      | 0.400   |
| 3             | 102| 190 [177–202]     | 0.014   | 151 [137–165]      |         |
| CA125         |    |                   |         |                    |         |
| ≤35 U/ml      | 80 | 149 [130–168]     | 0.126   | 91 [77–106]        | <0.001  |
| >35 U/ml      | 226| 166 [155–176]     | 0.017   | 149 [138–159]      |         |
| Chemosensitivity |    |                   |         |                    |         |
| Sensitive     | 147| 168 [156–179]     | 0.017   | 138 [127–149]      | 0.001   |
| Resistant     | 43 | 193 [175–211]     | 0.017   | 181 [158–204]      |         |

Table 1. Correlation between PAUF and TLR4 expression with clinicopathologic characteristics of ovarian cancer. Protein expression was determined through analysis of an immunohistochemically stained tissue array, as described in the Materials and methods section. p values were measured using t-test or ANOVA. p values < 0.05 are marked in bold.
PAUF was previously reported as an endogenous ligand for TLR4, and activates the mitogen-activated protein kinase pathway in THP-1 cells. PAUF also activates the TPL2/MEK/ERK signaling pathway, resulting in an increase of AP-1 regulated gene expression and promoting escape from innate immune surveillance and tumor growth. In addition, Kang et al. showed that PAUF induces activation and maturation of dendritic cells by stimulating the TLR signaling pathway. They showed that treatment with PAUF or lipopolysaccharide (LPS) induces production of IL-23 in maturing dendritic cells in a TLR4-dependent manner. Recently the change of tumor microenvironment by activation of TLR4 was reported in different types of cancer including diffuse large B-cell lymphoma, breast and prostate cancers. It postulates that the delicate balance of PAUF/TLR activation in the tumor microenvironment in different cell types helps to shape the inflammatory profile and outcome of tumor growth or regression. Song et al. reported that PAUF enhances accumulation of tumor-infiltrating myeloid-derived suppressor cells and its immune suppressive function via TLR4-mediated signaling pathway in PAUF-overexpressing tumor cell-injected mice. With further studies, specific activation or repression of PAUF/TLRs can be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy for some ovarian cancer patients.

In summary, we showed that PAUFhigh and TLR4high expression is associated with aggressive tumor phenotypes and is an independent prognostic factor for progression-free survival, while TLR4high and PAUFhigh/TLR4high is poor prognostic factor for overall survival in epithelial ovarian cancer. Furthermore, we demonstrated...
that PAUF could induce cancer cell activation and cancer proliferation via ERK, JNK, and p38 activation. Further characterization of the mechanism of PAUF in chemoresistance will aid the development of novel treatments for epithelial ovarian cancer.

**Methods**

**Patients and tumor samples.** A total of 72 normal epithelial tissues, 69 benign tumor tissues, 62 borderline tumors, 205 epithelial ovarian cancers and 52 metastatic tumors were obtained from patients who underwent surgical treatment at Gangnam Severance Hospital between 1996 and 2010 and the Korea Gynecologic Cancer Bank (NRF-2012M3A9B8021800). All procedures were conducted in accordance with the Declaration of Helsinki. All study participants provided written informed consent tissue samples with the Institutional Review Board of Samsung Medical Center (approval no. 2015-07-122; Seoul, South Korea).

Ovarian cancers were classified based on the International Federation of Gynecology and Obstetrics (FIGO) staging system and the WHO grading system. All patients were treated with maximal debulking surgery, followed by combination treatment with paclitaxel/carboplatin. The clinicopathological features are summarized in Table 1. After platinum based chemotherapy, follow-up examinations were done every 3 months for the first 2 years, 6 months for the next 3 years and subsequent annual checkups. Progression-free survival was evaluated

**Figure 4.** The associations between PAUF and TLR4 in patients with epithelial ovarian cancer. (A) TLR4 expression was positively correlated with expression of PAUF ($r = 0.256$, $p = 0.001$). (B) PAUF expression showed significant positive correlations with TLR4 expression in advanced stage (stage III/IV; $r = 0.279$, $p = 0.002$) and grade 3 ($r = 0.346$, $p = 0.001$).
from the date of surgery to the period of recurrence/progression or the time of the last follow-up visit. Overall survival was assessed from the date of surgery to patient death, or the date of last contact, for living patients.

Immunohistochemistry. Tissue cylinders of 1.0 mm diameter were extracted from the most representative areas of donor blocks and transplanted into recipient blocks using a tissue arrayer (Beecher Instruments, Inc., Silver Spring, MD). According to the block, 2–3 punches from each patient were included in the TMA, and the final expression values were averaged. For the assessment of PAUF and TLR4 expression, 5-μm TMA sections were used for immunohistochemical staining as described previously. Antigen recovery was performed in heat-activated antigen retrieval buffer of pH 9.0 (for PAUF) or pH 6.0 (for TLR4) (Dako, Carpinteria, CA). For TLR4, additional protein blocking (Dako) was applied for 15 min. The TMA slides were incubated at room temperature with anti-PAUF mouse monoclonal antibody (clone no. 817310; R&D Systems, Minneapolis, MN) at 1:100 dilution for 2 h, mouse monoclonal anti-TLR4 antibody (NB100–56566: Novus Biologicals, Littleton, CO) at 1:250 dilution for 1 h. The sections were incubated with with EnVision+ Dual Link System-HRP (Dako) for 30 min, visualized with DAB+ (3, 3′-Diaminobenzidine; Dako) for 10 min, and counterstained with hematoxylin.

Table 2. Univariate and multivariate analyses for progression-free survival. FIGO, International Federation of Gynecology and Obstetrics. p values < 0.05 are marked in bold.
addition of chemiluminescent HRP Substrate (Millipore, Billerica, USA), immunoreactive bands were visualized (Enzo Life Sciences, New York, USA) or mouse IgG (Cell Signaling Technology) secondary antibodies. After 1000 diluted in 5% BSA and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit β (R&D Systems, MAB7777, USA), or anti-mouse #9212), phosphor-AKT (Cell Signaling Technology, #9271), total AKT (Cell Signaling Technology, #9272), PAUF (Cell Signaling Technology, #9251), phosphor-p38 (Cell Signaling Technology, #4511), total p38 (Cell Signaling Technology, #9251), phosphor-JNK (Cell Signaling Technology, #9251), total JNK (Cell Signaling Technology, #9251). In SDS-PAGE loading buffer (250 mM Tris-HCl, pH 6.8, 0.5 M DTT, 10% SDS, 0.5% bromophenol blue, 50% glycerol), subjected to electrophoresis, and transferred to PVDF membranes (Traub & Co., Basel, Switzerland). Membranes were probed with anti-rabbit phospho-ERK (Cell Signaling Technology, #9102, USA), total ERK (Cell Signaling Technology, #9101), phosphor-JNK (Cell Signaling Technology, #9251), total JNK (Cell Signaling Technology, #9251), phosphor-p38 (Cell Signaling Technology, #4511), total p38 (Cell Signaling Technology, #9212), phosphor-AKT (Cell Signaling Technology, #9271), total AKT (Cell Signaling Technology, #9272), PAUF (R&D Systems, MAB7777, USA), or anti-mouse β-actin (Santa Cruz Biotechnology, sc-47778, USA) antibodies 1000 diluted in 5% BSA and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Enzo Life Sciences, New York, USA) or mouse IgG (Cell Signaling Technology) secondary antibodies. After addition of chemiluminescent HRP Substrate (Millipore, Billerica, USA), immunoreactive bands were visualized.

Table 3. Univariate and multivariate analyses for overall survival. FIGO, International Federation of Gynecology and Obstetrics. p values < 0.05 are marked in bold.

| Risk factor                  | Univariate          | Multivariate         |
|------------------------------|----------------------|----------------------|
|                              | Hazard Ratio [95% CI] | p value             | Hazard Ratio [95% CI] | p value             |
| Age (> 50)                   | 2.42 [1.26–4.63]     | 0.008                | 2.34 [1.16–4.69]     | 0.017                |
| FIGO stage (III/IV)          | 4.20 [1.49–11.8]     | 0.007                | 2.91 [1.02–8.27]     | 0.045                |
| Cell type (others vs. serous) | 0.33 [0.14–0.79]     | 0.012                | 0.58 [0.24–1.40]     | 0.224                |
| Grade (3 vs. 1/2)            | 1.88 [1.01–3.52]     | 0.048                | 2.05 [1.06–3.96]     | 0.033                |
| PAUF High                    | 1.92 [1.05–3.51]     | 0.034                | 1.83 [0.97–3.44]     | 0.062                |
| TLR4 High                    | 2.53 [1.34–4.8]      | 0.004                | 2.08 [1.04–4.15]     | 0.038                |
| PAUF High/TLR4 High          | 5.29 [1.97–14.19]    | 0.001                | 4.40 [1.48–13.06]    | 0.008                |

ELISA. SKOV3 and A2780 cells were purchased from ATCC (Manassas, VA). A total of 3 × 10⁵ SKOV3 and A2780 cells were cultured in opti-MEM media ( Gibco, Waltham, MA) for 48 h. Culture supernatant of cancer cells was used for the detection of PAUF by ELISA. Plates were coated with 4E6 capture antibodies (5 μg/ml) for 16 h at room temperature and then incubated with the supernatant of cultured cancer cells for 2 h. 11G6 detection antibodies (250 ng/ml) were added for 90 min at 37 °C, and then streptavidin–HRP (1:5000) was added for a further 30 min at 37 °C. PAUF expression level was detected at 450 nm.

Flow cytometry and intracellular staining. Cultured SKOV3 and A2780 cells were washed and stained with PE-conjugated anti–TLR4 antibodies (eBioscience, San Diego, CA) for confirmation of surface staining or washed, fixed, permeabilized using a BD cytofix/cytoperm Plus kit (BD Bioscience, San Jose, CA), and stained with PE-conjugated TLR4 antibodies for confirmation of intracellular TLR4 level. Cells were analyzed on a FACScalibur using CELL Quest software (BD Bioscience).

Transfection. A2780 (4 × 10⁵) and SKOV3 (2 × 10⁵) cells were cultured in 6-well plates. Cells were cultured in opti-MEM for 1 h and then incubated with 400 pmol of control siRNA (Cosmo Genetech, Seoul, Korea) (Sense: 5′-UCCCUUGGUAUUCUCCACCAUGGCU-3′, Antisense: 5′-AGCCUUAGGUGGAAUACCA GGAA-3′)⁴⁵, TLR4 #1 siRNA (Sense: 5′-GGGCUUAGAAACAAUCAAGAATT-3′, Antisense: 5′-UUCUAG UUGUUCUAGGCCCTT) (Sigma, NM_138554, Missouri 63103, USA), TLR4 #2 siRNA (Sense: 5′-CGAUGUAU UAUUGACUAAUU-3′, Antisense: 5′-UAUGUCUAAUUAUCAUCG-3′), PAUF #1 siRNA (Sense: 5′-UCCCUUGG UAUUCUCCACCAUGGCU-3′, Antisense: 5′-AGCUGUAGGGGAUAUCCAGGA-3′) or PAUF #2 siRNA (Sense: 5′-AAAUGAAUAAUGCCGUCUUCGUGG-3′, Antisense: 5′-CCAGGAAGGCCGUUUUCUA UUU-3′, Cosmo Genetech) for 8 h with lipofectamine RNAi max (Invitrogen, Waltham, MA). Cells were washed and cultured for 48 h. One more transfection was conducted, and cells were incubated for 18 h.

Western blot analysis. To confirm intracellular PAUF expression level or cell signaling activation after siRNA transfection and treatment with recombinant PAUF, A2780 and SKOV3 cells were cultured in 100-mm culture plates. After transfection with control, PAUF #1, PAUF #2, TLR4 #1 or TLR4#2 siRNA, cells were starved in 6-well plates for 16 h and incubated with or without recombinant PAUF protein (5 μg/ml) for 20 min. Cells were washed, collected, centrifuged, and lysed with protein extraction RIPA solution (50 mM Tris–Cl [pH 8.0], 150 mM NaCl, 1 mM phenylmethylsulphonyl fluoride [PMSF], 0.1% sodium dodecyl sulfate [SDS], 1% Nonidet P-40 [NP-40], and 0.5 mM EDTA; Elpis Biotech, Daejeon, Korea) for 1 h on ice. Protein concentrations were determined using a Bradford protein assay kit (Pierce, Waltham, MA). Equal amounts of protein were solubilized in SDS-PAGE loading buffer (250 mM Tris–HCl, pH 6.8, 0.5 M DTT, 10% SDS, 0.5% bromophenol blue, 50% glycerol), subjected to electrophoresis, and transferred to PVDF membranes (Traub & Co., Basel, Switzerland). Membranes were probed with anti-rabbit phospho-ERK (Cell Signaling Technology, #9102, USA), total ERK (Cell Signaling Technology, #9101), phosphor-JNK (Cell Signaling Technology, #9251), total JNK (Cell Signaling Technology, #9251), phosphor-p38 (Cell Signaling Technology, #4511), total p38 (Cell Signaling Technology, #9212), phosphor-AKT (Cell Signaling Technology, #9271), total AKT (Cell Signaling Technology, #9272), PAUF (R&D Systems, MAB7777, USA), or anti-mouse β-actin (Santa Cruz Biotechnology, sc-47778, USA) antibodies 1000 diluted in 5% BSA and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Enzo Life Sciences, New York, USA) or mouse IgG (Cell Signaling Technology) secondary antibodies. After addition of chemiluminescent HRP Substrate (Millipore, Billerica, USA), immunoreactive bands were visualized.

Negative controls including mouse immunoglobulin G (IgG) isotype control and omission of the primary antibody were performed (Supplementary Fig. S5). Pancreatic adenocarcinoma and lymph nodes were used as positive controls.

Quantitative digital image analysis of immunohistochemical stains was performed using Visiopharm integrator system (VIS) for Windows 7, version 4.5.1.324 (Visiopharm, Hoersholm, Denmark) as described previously⁴⁶. In brief, slides were scanned using bright field imaging at ×20 magnification (NanoZoomer 2.0 HT; Hamamatsu Photonics, Hamamatsu City, Japan). The brown-colored (3, 3′-Diaminobenzidine) staining intensity was calculated using a predefined algorithm setting. The overall protein expression was expressed as mean value of histoscore, which is the multiplication of the intensity score (0–3) and percentage of stained cells, with a maximum of 300⁴⁷.
by an enhanced chemiluminescence reaction. The intensity of bands was determined using ImageQuant software (Ver. 5.2, GE Healthcare, Piscataway, USA). The ratio is the intensity ratio compared to the western blot intensity of scramble siRNA-treated cells.

**Cell proliferation.** SKOV3 (2 × 10^4) and A2780 (4.5 × 10^5) cells untransfected or transfected with control, TLR4#1, TLR4 #2, PAUF #1 or PAUF #2 siRNA were cultured with PAUF protein (1 μg/ml) day after day in 96-well white plates (SPL Life Sciences, Pocheon, Korea). Cell proliferation was measured from one to four days using a Cell Titer-Glo luminescence assay kit (Promega, Madison, WI).

**Statistical analysis.** Statistical analysis was performed with R statistical software version 3.4.1. Student’s t test or ANOVA test was used to test possible associations between immunohistochemical expression of the proteins and clinicopathological factors. Spearman’s rank correlation coefficient was used to assess the correlations between expressions of each protein. For survival analysis, samples were categorized as positive or negative using the cutoff values showing the greatest discriminative power in a Cox model of progression-free survival (R package: survMisc). Kaplan-Meier survival curves were plotted and the log rank test was used to compare survival between groups. Survival distributions were plotted using the Kaplan–Meier method, and the relationship between survival and each parameter was analyzed with the log-rank test. A multivariable Cox proportional hazards model was used to identify independent prognostic factors of survival. P-values of 0.05 or less were considered statistically significant.

**References**

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. *CA Cancer J Clin* **60**, 277–300 (2010).
2. Runnebaum, I. B. & Stickeler, E. Epidemiological and molecular aspects of ovarian cancer risk. *J Cancer Res Clin Oncol* **127**, 73–79 (2001).
3. Kim, K. & Ryu, S. Y. Major clinical research advances in gynecologic cancer 2009. *J Gynecol Oncol* **20**, 203–209 (2009).
4. McGuire, W. P. 3rd. & Markman, M. Primary ovarian cancer chemotherapy: current standards of care. *Br J Cancer* **89**(Suppl 3), S3–8 (2003).
5. du Bois, A. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* **95**, 1320–1329 (2003).
6. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet* **360**, 305–315 (2002).
7. DeNardo, D. G., Johansson, M. & Cousens, L. M. Immune cells as mediators of solid tumor metastasis. *Cancer Metastasis Rev* **27**, 11–18 (2008).
8. Karin, M. & Goret, F. R. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* **5**, 749–759 (2005).
9. Burke, E., Reif, M., Negus, R. & Balkwill, F. A cytokine profile of normal and malignant ovary. *Cytokine* **8**, 578–585 (1996).
10. Penson, R. E. et al. Cytokines (IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα) in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. *Int J Gynecol Cancer* **10**, 33–41 (2000).
11. Nowak, M. et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. *Neuro Endocrinol Lett* **31**, 375–387 (2010).
12. Clendenen, T. V. et al. Circulating inflammation markers and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* **20**, 799–810 (2011).
13. Cubillos-Ruiz, J. R., Rutkowski, M. & Contejo-Garcia, J. R. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. *Cell Cycle* **9**, 260–268 (2010).
14. Chen, R., Alvero, A. B., Silasi, D. A., Steffensen, K. D. & Mor, G. Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. *Oncogene* **27**, 225–233 (2008).
15. Chen, R., Alvero, A. B., Silasi, D. A. & Mor, G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. *Am J Reprod Immunol* **57**, 93–107 (2007).
16. Goutagny, N., Estornes, Y.,Hasan, U., Lebecque, S. & Caux, C. Targeting pattern recognition receptors in cancer immunotherapy. *Target Oncol* **7**, 29–54 (2012).
17. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. *Nature* **454**, 436–444 (2008).
18. Pinto, A., Morello, S. & Sorrentino, R. Lung cancer and Toll-like receptors. *Cancer Immunol Immunother* **60**, 1211–1220 (2011).
19. Rakoff-Nahoum, S. & Medzhitov, R. Toll-like receptors and cancer. *Nat Rev Cancer* **9**, 57–63 (2009).
20. Yu, L. & Chen, S. Toll-like receptors expressed in tumor cells: targets for therapy. *Cancer Immunol Immunother* **57**, 1271–1278 (2008).
21. Kim, S. A. et al. Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. *Cancer Sci* **100**, 828–836 (2009).
22. Lee, Y. et al. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. *Oncogene* **29**, 56–67 (2010).
23. Choi, C. H. et al. Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients. *Hum Pathol* **46**, 884–893 (2015).
24. Kim, S. J. et al. Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability. *Oncogene* **32**, 3638–3647 (2013).
25. Park, H. D. et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. *Oncogene* **30**, 201–211 (2011).
26. Kelly, M. G. et al. TLR-4 signaling promotes tumor growth and paclitaxel chemo-resistance in ovarian cancer. *Cancer research* **66**, 3859–3868 (2006).
27. Szafranek, M. et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemo-resistance in ovarian cancer. *Oncogene* **28**, 4353–4363 (2009).
28. Zhou, M. et al. Toll-like receptor expression in normal ovary and ovarian tumors. *Cancer Immunol Immunother* **58**, 1375–1385 (2009).
29. Luo, X. Z., He, Q. Z. & Wang, K. Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. *Int J Clin Exp Med* **8**, 14323–14327 (2015).
30. Kim, S. K. et al. Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. *Int J Clin Exp Pathol* **7**, 5103–5110 (2014).
31. Eltabbakh, G. H. & Awtrye, C. S. Current treatment for ovarian cancer. *Expert Opin Pharmacother* **2**, 109–124 (2001).
32. Itamochi, H., Kigawa, J. & Terakawa, N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99, 653–658 (2008).
33. Itamochi, H. et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93, 723–728 (2002).
34. Xu, Z. et al. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13, 511–519 (2002).
35. Kang, T. H. et al. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget 6, 27751–27762 (2015).
36. Wang, X. et al. Toll-like receptor 4-induced inflammatory responses contribute to the tumor-associated macrophages formation and infiltration in patients with diffuse large B-cell lymphoma. Annals of diagnostic pathology 19, 232–238 (2015).
37. Park, I. A. et al. Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Oncotarget 5, 59957–59964 (2016).
38. Riddell, J. R. et al. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer research 71, 1637–1646 (2011).
39. Song, J. et al. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. Oncotarget 7, 51840–51853 (2016).
40. Choi, C. H., Chung, J. Y., Kim, J. H., Kim, B. G. & Hewitt, S. M. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. J Transl Med 14, 124 (2016).

Acknowledgements
This research was supported by grants from the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research, and Samsung Medical Center (OTC1180321).

Author Contributions
C.H.C., T.H.K., J.-H.K. and S.M.H. conceived and planned the experiments. C.H.C., T.H.K., J.S.S., Y.S.K., E.J.C. and K.Y. performed experiments. C.H.C., T.H.K., E.J.C., S.K., S.S.K., J.-Y.C., J.-H.K. and S.M.H. contributed to the interpretation of the results. C.H.C., T.K.H. and J.-Y.C. wrote the manuscript in consultation with J.-H.K. and S.M.H. All authors provided critical feedback and helped the research and manuscript and reviewed the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-30582-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018